In 1975, the Durie-Salmon Staging System was developed to determine the stage of MM; it demonstrated the correlation between the amount of myeloma and the damage it causes, such as anemia and bone disease.

**Durie-Salmon Staging**

**Stage I:**All of the following must be present (hemoglobin >10g/dL, serum calcium ≤12mg/dL, absence of bone disease or solitary plasmacytoma, serum paraprotein <5g/dL if IgG or <3g/dL if IgA, urinary light chain excretion <4g/24h)

**Stage II:**Not fulfilling criteria of Durie-Salmon stage I or III

**Stage III:**Any of the following may be present (hemoglobin <8.5g/dL, serum calcium >12 mg/dL, skeletal survey with >2 lytic lesions, serum paraprotein >7g/dL if IgG, >5g/dL if IgA, urinary light chain excretion >2g/24h)

In 2005, the International Myeloma Work Group (IMWG) introduced the International Staging System (ISS) that uses serum albumin and beta-2 microglobulin for staging the disease.

**International Staging System**

**Stage I:**

- Serum beta-2 microglobulin <3.5 mg/L

- Serum albumin ≥3.5g/dL

**Stage II:**

- Serum beta-2 microglobulin <3.5 mg/L

- Serum albumin <3.5g/dL

Or serum beta-2 microglobulin 3.5 to 5.5 mg/L irrespective of serum albumin

**Stage III:**serum beta-2 microglobulin >5.5 mg/L

In 2015, IMWG incorporated genetic risk assessed by fluorescence in-situ hybridization(FISH) and lactate dehydrogenase (LDH) called Revised-ISS (R-ISS):

**Revised-International Staging System**

**Stage I:**

- Serum beta-2 microglobulin <3.5 mg/L

- Serum albumin ≥3.5 g/dL

- Standard-risk chromosomal abnormalities by FISH

- Normal LDH

**Stage II:**Not R-ISS stage I or III

**Stage III:**Serum beta 2-microglobulin ≥5.5 mg/L and either high-risk chromosomal abnormalities by FISH OR high LDH.